Dominik Steubl
Company: Boehringer Ingelheim
Job title: CPL
Seminars:
Examining Clinical Trial Design for Phase 2 CKD Studies to Provide Confidence in Endpoints, Sample Size & Outcome Predictions 1:00 pm
Explore strategies for designing Phase 2 trials that are more predictive of Phase 3 success, focusing on proper patient stratification and using surrogate markers effectively to gauge outcomes early on Review the challenges of selecting appropriate Phase 2 endpoints and sample sizes, ensuring that trial design is robust enough to provide meaningful data while balancing…Read more
day: Day One Track 2 PM
Mastering Hierarchical Composite Endpoints: Challenges & Opportunities in CKD Trials 1:30 pm
Hierarchical composite endpoints (HCEs) combine multiple clinical and surrogate endpoints in a single trial, providing a pathway to demonstrate efficacy across various outcomes in CKD trials. However, the complexity of developing, ranking, and interpreting HCEs presents unique challenges, especially in CKD trials where surrogate endpoints such as proteinuria or GFR slope play a critical role.…Read more
day: Pre-Conference Workshop C
Panel Discussion & Audience Roundtable: Advancing Therapeutics in Glomerular Diseases: What’s Next? 2:30 pm
Discuss the need to identify reliable surrogate markers for other glomerular diseases and potential avenues for development and standardization Discuss what can be learned from the established biomarkers in IgA nephropathy to improve patient outcomes in other glomerular diseases Examine the variability in pathology and clinical presentation among glomerular disease patients, and what strategies can…Read more
day: Pre-Conference Focus Day
Panel Discussion: IgA Nephropathy: Current Achievements, Unmet Needs, & Research Priorities 8:30 am
Explore a comprehensive overview of breakthroughs in IgAN therapies that improve renal outcomes. How far have we come in slowing disease progression and reducing proteinuria? Despite advancements, where do gaps still persist? Distil the limitations of existing therapies, variability in patient responses, and the challenges of predicting long-term outcomes. What hurdles remain for patients and…Read more
day: Pre-Conference Focus Day